The Spanish Biondustry Association (AseBio) has held the fifth edition of the AseBio Investor Day at the Kursaal in San Sebastian (Donostia), with the support of the Provincial Council of Gipuzkoa and ICEX Spain Export and Investment-Invest in Spain.

In its fifth edition, AseBio Investor Day 2024 brought together nearly 280 attendees from more than 180 organizations and 19 countries, including 70 investors from more than 55 investment entities. Almost 300 one-to-one meetings were held at the event.

Alberto Sanz, Director of Financing and Investor Relations at ICEX - Invest in Spain, participated in this forum in which he stressed that "Spain is very well positioned to attract biotech R&D projects, due to both the excellent quality of its researchers and its capacity to attract international talent".

AseBio Investor Day is a unique platform that brings together entrepreneurs, investors and industry leaders to share ideas and knowledge. "It is an example of the commitment of AseBio and the other players involved to boost the growth of the Spanish biotechnology industry. I am confident that many of the meetings that are taking place now will result in investment rounds that will accelerate the growth of our biotech companies," said AseBio's president, Rocío Arroyo.

Spanish biotech companies raise 37% more private funding in 2023
AseBio announced the new financing figures for the biotechnology industry at this conference, which secured €228 million in private investment, a figure that represents an increase of 37% over the total volume raised in 2022.

According to this organization's figures (the data are part of the AseBio 2023 Report to be published on 12 June), the average turnover stood at €5.4 million.

In 2020 there were four transactions exceeding €10 million; in 2021 there were five; in 2022, three; and in 2023, five. In this regard, it is worth noting that the number of transactions has decreased to 42 compared to 2022.

Some of these transactions have been supported by CDTI's INNVIERTE programme, which committed almost €29 million in 2023. Since the launch of this co-investment instrument in 2019, it has committed a total of €101 million to 35 biotech companies.

The biotechnology industry remains in the sights of international players, both corporations acquiring Spanish companies and international investors supporting the disruptive innovations they are developing.